Treatment of Multiple Attacks of Acute Migraine (0462-025)

• Status: Completed
• Trial end date: 1996-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate rizatriptan for the treatment of multiple attacks of acute migraine compared to placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rizatriptan

Criteria

Inclusion Criteria:

• Patient had at least a 6-month history of migraine, with or without aura

• Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions.

• Patient was judged to be in good health, apart from migraine

Exclusion Criteria:

• Patient was pregnant or a nursing mother.

• Patient had abused drugs or alcohol within 12 months prior to entering the study

• Patient had a history of cardiovascular disease

• Patient had clinically significant ECG abnormality

• Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening

• Patient received treatment with an investigational device or compound within 30 days of the study start

• Patient typically suffered from less then 1 or more than 8 attacks of migraine per month

• Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches

• Patient had prior exposure to rizatriptan